Compass Therapeutics Reports Q3 2026 Results, $27.2 Million Net Loss
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, versus a $14.3 million loss a year earlier. It ended the quarter with $163 million in cash and marketable securities, which it expects to fund operations into 2028.
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, compared with a $14.3 million loss a year earlier. The company ended the quarter with $163 million in cash and marketable securities, which it expects to fund operations into 2028. It also provided upd…